Rigel Pharmaceuticals Inc. [NASDAQ: RIGL] gained 1.23% or 0.03 points to close at $2.47 with a heavy trading volume of 3545027 shares. The company report on October 9, 2020 that Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova.
Trial being conducted at NIH Clinical Center in Bethesda, Maryland and Inova Fairfax Hospital in Virginia.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel’s oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova® Health System. Fostamatinib, marketed in the U.S. as TAVALISSE® (fostamatinib disodium hexahydrate) tablets, is approved in the U.S. and Europe as a treatment for adult chronic immune thrombocytopenia (ITP).
It opened the trading session at $2.43, the shares rose to $2.49 and dropped to $2.37, the range by which the price of stock traded the whole day. The daily chart for RIGL points out that the company has recorded 35.71% gains over the past six months. However, it is still -100.81% lower than its most recent low trading price.
If we look at the average trading volume of 3.11M shares, RIGL reached to a volume of 3545027 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Rigel Pharmaceuticals Inc. [RIGL]:
Cantor Fitzgerald have made an estimate for Rigel Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 15, 2019. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 26, 2019, representing the official price target for Rigel Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $9 to $7, while Cantor Fitzgerald kept a Overweight rating on RIGL stock.
The Average True Range (ATR) for Rigel Pharmaceuticals Inc. is set at 0.14, with the Price to Sales ratio for RIGL stock in the period of the last 12 months amounting to 3.93. The Price to Book ratio for the last quarter was 6.68, with the Price to Cash per share for the same quarter was set at 0.54.
Trading performance analysis for RIGL stock
Rigel Pharmaceuticals Inc. [RIGL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.89. With this latest performance, RIGL shares gained by 6.93% in over the last four-week period, additionally plugging by 35.71% over the last 6 months – not to mention a rise of 6.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RIGL stock in for the last two-week period is set at 48.18, with the RSI for the last a single of trading hit 45.21, and the three-weeks RSI is set at 49.71 for Rigel Pharmaceuticals Inc. [RIGL]. The present Moving Average for the last 50 days of trading for this stock 2.45, while it was recorded at 2.47 for the last single week of trading, and 2.17 for the last 200 days.
Rigel Pharmaceuticals Inc. [RIGL]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Rigel Pharmaceuticals Inc. [RIGL] shares currently have an operating margin of -116.53 and a Gross Margin at +98.47. Rigel Pharmaceuticals Inc.’s Net Margin is presently recorded at -112.83.
Return on Total Capital for RIGL is now -69.09, given the latest momentum, and Return on Invested Capital for the company is -69.42. Return on Equity for this stock declined to -81.73, with Return on Assets sitting at -46.67. When it comes to the capital structure of this company, Rigel Pharmaceuticals Inc. [RIGL] has a Total Debt to Total Equity ratio set at 67.48. Additionally, RIGL Total Debt to Total Capital is recorded at 40.29, with Total Debt to Total Assets ending up at 24.61. Long-Term Debt to Equity for the company is recorded at 53.96, with the Long-Term Debt to Total Capital now at 32.22.
Reflecting on the efficiency of the workforce at the company, Rigel Pharmaceuticals Inc. [RIGL] managed to generate an average of -$410,393 per employee. Receivables Turnover for the company is 8.36 with a Total Asset Turnover recorded at a value of 0.41.Rigel Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.30.
Rigel Pharmaceuticals Inc. [RIGL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Rigel Pharmaceuticals Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 36.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RIGL.
An analysis of insider ownership at Rigel Pharmaceuticals Inc. [RIGL]
There are presently around $356 million, or 88.10% of RIGL stock, in the hands of institutional investors. The top three institutional holders of RIGL stocks are: FMR LLC with ownership of 21,462,703, which is approximately -2.651% of the company’s market cap and around 0.31% of the total institutional ownership; BLACKROCK INC., holding 17,219,104 shares of the stock with an approximate value of $42.53 million in RIGL stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $38.58 million in RIGL stock with ownership of nearly -0.559% of the company’s market capitalization.
Positions in Rigel Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 73 institutional holders increased their position in Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] by around 14,472,797 shares. Additionally, 39 investors decreased positions by around 19,452,113 shares, while 32 investors held positions by with 110,209,845 shares. The mentioned changes placed institutional holdings at 144,134,755 shares, according to the latest SEC report filing. RIGL stock had 22 new institutional investments in for a total of 2,996,648 shares, while 5 institutional investors sold positions of 151,811 shares during the same period.